Skip To Main Content
C.H. Barcenas on Muck Rack

C.H. Barcenas

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with C.H.

Contact C.H., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial

|
By S.A. Hurvitz, R. Bose, St Louis, C.H. Barcenas
| annalsofoncology.org
HIGHLIGHTS • CONTROL trial investigated anti-diarrheal strategies including dose escalation in neratinib-treated patients with early HER2+ breast cancer • Both preemptive prophylaxis and dose escalation reduced the rate, severity, and duration of grade ≥3 diarrhea compared with ExteNET • Lower diarrhea-related discontinuations and dose reductions in multiple cohorts compared with ExteNET suggested improved tolerability • Neratinib dose escalation is a particularly promising strategy as it...
Open in Who Shared Issue with article?
See all 1 articles